Notes and operational analysis on the commercialization, funding, and governance of biomedical innovation.
I. Science & Clinical Translation
Twenty-Five Years of Global Private Investment in Pediatric Orthopaedic Start-ups
A new study mapping 25 years of private backing reveals that pediatric orthopaedic start-ups face severe underinvestment, accounting for just 5% of total invested dollars in the field.
Ten-Year Trends in How Early-Stage Sepsis Start-Ups Receive Investment
A ten-year macro-level analysis of venture capital allocation across burgeoning healthcare technologies, exploring the distinct investment disparity between oncology and high-prevalence critical care spaces.
Sepsis Needs Diagnostic Start-Ups. A Lot of Them
An examination of the structural, commercial, and financial hurdles facing university-based investigators attempting to translate early-stage diagnostic discoveries into viable, venture-backed innovations.
II. Capital Preservation & Diligence
Financial Elements in a Fume Date Calculation
An operational analysis of why start-ups miscalculate cash runways, how accrual accounting masks insolvency triggers, and the explicit liabilities required to execute a controlled corporate wind-down.
III. Fiduciary Governance & Policy
Genomic and Clinical Informatic Biorepository Strategic Diagnostic
An operational strategic diagnostic detailing how ArgoPond evaluated a 60,000+ participant enterprise biorepository, audited over 70 uncoordinated facilities, and built a 10-year Monte Carlo capital planning model to de-risk institutional governance and commercial BioPharma partnerships.
Initial Receiver Assessment of Director and Officer Insurance Policies
A practical framework evaluating the structural overlap between D&O coverage limits, director liability, and asset recovery mechanics for a corporate estate at the onset of financial distress or regulatory enforcement.
The Innovation Pipeline: From Universities to Small Businesses
An operational assessment before the U.S. House Committee on Small Business regarding capital distribution bottlenecks in technology transfer. A structural analysis of federal SBIR/STTR funding models, the alignment mismatch between academic reviewers and commercialization targets, and the mechanism’s role in scaling regional biotech ecosystems.